Resource Logo
AIDS Weekly Plus

Research Conducted at Mount Sinai Medical Center Has Updated Our Knowledge about AIDS/HIV Research




 



2012 DEC 24 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- A new study on AIDS/HIV Research is now available. According to news reporting originating in New York City, New York, by NewsRx journalists, research stated, "The apolipoprotein E (APOE) epsilon 4 allele enhances cerebral accumulation of beta-amyloid (A beta) and is a major risk factor for sporadic Alzheimer's disease. We hypothesized that HIV-associated neurocognitive disorders (HAND) would be associated with the APOE epsilon 4 genotype and cerebral A beta deposition."

The news reporters obtained a quote from the research from Mount Sinai Medical Center, "Clinicopathological study of HIV-infected adults from four prospective cohorts in the US National NeuroAIDS Tissue Consortium. We used multivariable logistic regressions to model outcomes [A beta plaques (immunohistochemistry) and HAND (standard criteria)] on predictors [APOE epsilon 4 (allelic discrimination assay), older age (>= 50 years), A beta plaques, and their two-way interactions] and comorbid factors. Isocortical A beta deposits generally occurred as diffuse plaques and mild-to-moderate amyloid angiopathy. Isocortical phospho-Tau-immunoreactive neurofibrillary lesions were sparse. The APOE epsilon 4 and older age were independently associated with the presence of A beta plaques [adjusted odds ratio (OR) 10.16 and 5.77, 95% confidence interval (CI) 2.89-35.76 and 1.91-17.48, P=0.0003 and 0.0019, respectively, n=96]. The probability of HAND was increased in the presence of Ab plaques among APOE epsilon 4 carriers (adjusted OR 30.00, 95% CI 1.41-638.63, P=0.029, n=15), but not in non-epsilon 4 carriers (n=57). The APOE epsilon 4 and older age increased the likelihood of cerebral A beta plaque deposition in HIV-infected adults. Generally, A beta plaques in HIV brains were immunohistologically different from those in symptomatic Alzheimer's disease brains. Nonetheless, A beta plaques were associated with HAND among APOE epsilon 4 carriers."

According to the news reporters, the research concluded: "The detection of APOE epsilon 4 genotype and cerebral Ab deposition biomarkers may be useful in identifying living HAND patients who could benefit from A beta-targeted therapies."

For more information on this research see: Cerebral beta-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE epsilon 4 carriers. Aids, 2012;26(18):2327-2335. Aids can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Lippincott Williams and Wilkins - www.lww.com; Aids - journals.lww.com/aidsonline/pages/default.aspx)

Our news correspondents report that additional information may be obtained by contacting V. Soontornniyomkij, Mt Sinai Med Center, Manhattan HIV Brain Bank, New York, NY 10029, United States (see also AIDS/HIV Research).

Keywords for this news article include: Amyloid, HIV/AIDS, Proteins, RNA Viruses, Retroviridae, New York City, United States, HIV Infections, AIDS/HIV Research, Vertebrate Viruses, Primate Lentiviruses, North and Central America, Viral Sexually Transmitted Diseases

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC



 


Copyright © 2012 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.



Information in this article was accurate in December 24, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.